Long-term safety and efficacy of tralokinumab in patients with moderate-to-severe atopic dermatitis treated for up to 6 years: final results from the open-label extension trial ECZTEND / Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, Andreas Wollenberg, Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimanesh, Ann-Marie Tindberg, Kristian Reich